1	Daily consumption of ketone ester, bis-octanoyl (R)-1,3-butanediol, is safe and tolerable
2	in healthy older adults, a randomized, parallel arm, double-blind, placebo-controlled,
3	pilot study.
4	
5	Brianna J. Stubbs ^{a*} , Elizabeth B. Stephens ^a , Chatura Senadheera ^a , Sawyer Peralta ^a , Stephanie
6	Roa-Diaz ^a , Laura Alexander ^a , Wendie Silverman-Martin ^a , Thelma Y. Garcia ^a , Michi
7	Yukawa ^{b, c} , Jenifer Morris ^c , Traci M. Blonquist ^d , James B. Johnson ^e , John C. Newman ^{a, b}
8	
9	^a Buck Institute for Research on Aging, 8001 Redwood Blvd, Novato, CA, USA, 94945-1400
10	^b Division of Geriatrics, UCSF, 3575 Geary Blvd, Fl 1, San Francisco, CA, USA, 94118-
11	3212.
12	^c Geriatrics, San Francisco VA Medical Center, 4150 Clement St, San Francisco, CA, USA,
13	94121-1563.
14	^d Biofortis, Mérieux NutriSciences, 800-A South Rohling Rd, Addison, IL, USA, 60101-
15	4219.
16	^e Independent Researcher, Greenbrae, CA, USA.
17	
18	SHORT TITLE: Ketone ester safety and tolerability in older adults
19	* Correspondence: Dr. Brianna J. Stubbs: <u>bstubbs@buckinstitute.org</u> ;
20	Dr. John C. Newman jnewman@buckinstitute.org;
21	8001 Redwood Blvd, Novato, CA, USA 94945-1400
22	

23 Abbreviations

ALT	Alanine Transaminase
AST	Aspartate Aminotransferase
BH-BD	Bis-hexanoyl (R)-1,3-butanediol
ВНВ	Beta-hydroxybutyrate
BIKE	Buck Institute Ketone Ester
BMI	Body Mass Index
BO-BD	Bis-octanoyl (R)-1,3-butanediol
BTQ	Beverage Tolerability Questionnaire
CI	Confidence Interval
GI	Gastrointestinal
HDL	High Density Lipoprotein
ITT	Intent to Treat
KE(s)	Ketone Ester(s)
LDL	Low Density Lipoprotein
МСТ	Medium Chain Triglyceride
PLA	Placebo
РР	Per Protocol
T4	Thyroxine

24

26 Abstract

Objectives: Ketone bodies are endogenous metabolites produced during fasting or a ketogenic diet that have pleiotropic effects on aging pathways. Ketone esters (KEs) are compounds that induce ketosis without dietary changes, but KEs have not been studied in an older adult population. The primary objective of this trial was to determine tolerability and safety of KE ingestion in older adults.

32 **Design:** Randomized, placebo-controlled, double-blinded, parallel-arm trial, with a 12-week

intervention period (**NCT05585762**).

³⁴ Setting: General community, Northern California, USA.

Participants: Community-dwelling older adults, independent in activities of daily living, with no unstable acute medical conditions (n=30) were randomized and n=23 (M= 14, F=9) completed the protocol.

Intervention: Participants were randomly allocated to consume either KE (bis-octanoyl (R)1,3-butanediol) or a taste, appearance, and calorie-matched placebo (PLA) containing canola
oil.

Measurements: Tolerability was assessed using a composite score from a daily log for 2weeks, and then via a bi-weekly phone interview. Safety was assessed by vital signs and lab tests at screening and weeks 0, 4 and 12, along with tabulation of adverse events.

Results: There was no difference in the prespecified primary outcome of proportion of participants reporting moderate or severe nausea, headache, or dizziness on more than one day in a two-week reporting period (KE n =2 (14.3% [90% CI = 2.6 - 38.5]); PLA n=1 (7.1% [90% CI = 0.4 - 29.7]). Dropouts numbered four in the PLA group and two in the KE group. A greater number of symptoms were reported in both groups during the first two weeks; symptoms were reported less frequently between 2 – 12 weeks. There were no clinically relevant changes in safety labs or vital signs in either group.

51	Conclusions: This KE was safe and well-tolerated in healthy older adults. These results
52	provide a foundation for use of KEs in aging research.
53	Words Count: 305
54	Keywords: ketones, ketone ester, exogenous ketone, beta-hydroxybutyrate, safety, tolerance.
55	
56	Highlights
57	• Ketones esters induce ketosis without dietary changes and may target aging biology
58	• Studies of ketone esters were limited in duration and focused on younger adults
59	• We found ketone esters were safe and tolerable for 12 weeks in healthy older adults
60	

61 **1.0**

62 Introduction

Nutrition and aging have long been intertwined through years of research of the effects of 63 dietary restriction and fasting on aging in model organisms [1] and now humans (e.g. 64 CALERIE [2], HALLO-P (NCT05424042)). A deepening understanding of the molecular 65 mechanisms involved in fasting and dietary restriction has led to small molecule interventions 66 now under investigation in clinical trials targeting various aging phenotypes, as well as a 67 popular upswell of public and scientific interest in these dietary strategies as geroscience 68 interventions. Geroscience is a research paradigm based on addressing the biology of aging 69 and are-related disease. The geroscience approach of modulating fundamental aging 70 mechanisms holds promise for generating new therapeutics for multifactorial conditions of 71 aging which contribute to functional decline, disability, and loss of independence in older 72 adults [3, 4]. 73

A key shared element of the metabolic state induced by fasting and dietary restriction is 74 the production and oxidation of ketone bodies. Ketone bodies are small molecules synthesized 75 from lipids primarily in the liver, which circulate in the blood to provide non-glucose energy 76 to extrahepatic tissues. The most abundant circulating ketone body is beta-hydroxybutyrate 77 (BHB). Ketone bodies are synthesized constitutively at low concentrations, but are also 78 strongly induced during fasting [5]; during a prolonged fast, humans can produce up to ~ 150 g 79 of ketone bodies per day [6]. The energetic and molecular signaling activities of ketone 80 bodies, including supporting mitochondrial function and regulating inflammatory activation, 81 support a mechanistic role in modulating aging [7]. We, and others, previously demonstrated 82 that implementing a ketogenic diet, a nutritional method characterized by reduced 83 carbohydrate intake and increased fat intake without fasting, extended the healthy lifespan of 84 wild-type mice by slowing declines in overall aging-related functions, murine clinical frailty 85 scores, and muscle strength [8, 9]. 86

Exogenous ketones, including KEs, such as bis-octanoyl-(R)1,3-butanediol (BO-BD), are 87 small molecules that nutritionally deliver ketone bodies without other dietary changes [10, 88 11]. KEs are hydrolyzed in the gut to release ketogenic fatty acids and a ketogenic alcohol, 89 which are then metabolized in the liver, independent of insulin levels or fasting state, to 90 release ketone bodies [12]. In preclinical models, ketone bodies and KEs have been found to 91 impact multiple aging-relevant outcomes in the muscle [13, 14], heart [15, 16], and immune 92 system [17, 18]. Clinically, KEs have been shown to impact a range of endpoints in younger 93 adults, such as blood glucose control [19-22], physical [23-25], cognitive [26-28], immune 94 [29], and cardiovascular [28, 30] function. These examples support our central hypothesis that 95 ketone bodies delivered through KEs may be a candidate geroscience intervention, to target 96 clinical syndromes of aging via direct action on aging biology. However, studies of KE have 97 been limited in duration (28 days) and focused on younger adults; no KE has been studied in 98 an exclusively older adult population. 99

To be a feasible geroscience intervention, KE must be both tolerable and safe for daily, 100 prolonged use by older adults. Older adults are typically considered to be a more vulnerable 101 population, with a two-fold higher risk of hospitalization with adverse reactions to 102 interventions compared to younger counterparts [31]. One-month studies of KE in younger 103 adults have consistently demonstrated safety and generally good tolerance, although side 104 effects such as nausea, headache, upper abdominal pain, and diarrhea were occasionally 105 reported at mild intensity [32, 33]. Similarly, a 28-day study of bis hexanoyl (R)-1,3-106 butanediol (BH-BD), a KE that is closely related to BO-BD, reported an increased proportion 107 of young adult participants who experienced headache, nausea, and dizziness at least once in 108 the BH-BD group, but the absolute incidence was low, and severity was generally mild [34]. 109 The lack of data on KE use in older adults represents a major knowledge gap and barrier to 110 111 translation in this field.

To facilitate future aging-focused investigations using KE, we undertook this 12-week randomized, placebo-controlled, double-blinded, parallel arm, pilot clinical trial with the objective of generating the first human safety and tolerance data for KEs in a generalizable population of older adults, as well as the longest KE intervention study known to date. Based on the data with younger adults, we hypothesized that the KE would be safe and tolerable in healthy older adults.

118 **2.0**

- 119 Methods
- 120 **2.1**
- 121 Study Design

The Buck Institute Ketone Ester (BIKE) Study was a randomized, double-blind, placebo-122 controlled, parallel arm, pilot trial designed to assess the feasibility, safety, and tolerability of 123 up to 25 g/day of KE ingestion for 12 weeks compared to a placebo in older adults, 65 years 124 of age and older (Figure 1), in preparation for a planned study of KE in pre-frail older adults 125 (NIH funding ID: 1R01AG081226-01). Volunteers underwent consent and screening (Visit 126 1), and then were confirmed to be eligible for participation by medical officers. Upon 127 128 confirmation of eligibility, acute ketone kinetics were measured (Visit 2, results described in 129 [35]). Baseline safety measures were collected at day 0 (Visit 3), and daily KE or placebo consumption began at day 1. For 12 weeks (or until Visit 5), participants consumed one daily 130 serving of BO-BD or a visually, calorically and taste-matched placebo that contained a 131 132 matched mass of non-ketogenic fat (canola oil) formulated into a 75 mL beverage. Participants compelted a Beverage Tolerability Questionnaire (BTQ) after consuming the 133 study beverage each day for the first 14 days (acclimation period) to assess the tolerance of 134 the study beverage. Tolerance was further assessed by verbal administration of the BTQ 135 during phone calls every 2 weeks, starting at week 2. An interim safety assessment was 136 performed at week 4 (Visit 4). Upon completion of the 12 weeks, post-intervention safety 137 measures were collected, without study product consumption on the day of the test visit (Visit 138 139 5). An optional kinetics visit took place at least 1 week after Visit 5, measuring acute ketone kinetics after consumption of an equivalent serving of a newly developed powder formulation 140 of BO-BD. This study, and all study material was approved by Advarra IRB (WIRB-141 Copernicus Group, Puyallup, WA, ID# 20213716, current version 1.3 approved on 16th 142 October 2023) and was conducted in accordance with the Declaration of Helsinki. Signed 143

informed consent was provided by the participants prior to implementing any protocolspecific procedures. The study was registered in the clinicaltrials.gov database:
NCT05585762. Study visits took place at Buck Institute for Research on Aging (Novato, CA,
USA) between November 2022 - January 2024; the trial ended when the last enrolled subject
completed the protocol. Details of investigator and institutional conflict of interest
management plans can be found in our protocol paper [36].

150 **2.2**

151 **Participants and Screening**

Participants (n = 30) were community dwelling older adults (\geq 65 years of age) in stable 152 health. We aimed to enroll a broad sample of older adults, allowing common chronic diseases 153 and multiple medications to reflect the intended future study population. Specific exclusion 154 items were chosen based on possible interaction with anticipated KE side effects, such as 155 gastrointestinal (GI) upset. The full inclusion and exclusion criteria have been previously 156 described in our methods paper [36]. At the screening visit, participants completed a medical 157 158 history questionnaire in addition to assessment of height, weight, body mass index (BMI), vital signs, last menses (females only), current medication / supplement use, and review of 159 inclusion / exclusion criteria to determine eligibility. Additionally, blood and urine were 160 collected for analysis. This information was reviewed by a medical officer for approval to 161 participate. Participants had the opportunity to taste the study beverages to evaluate 162 palatability. Following medical officer approval, participants were randomized during Visit 2 163 based on order of enrollment to one of the study groups, based on a statistician-generated 164 block allocation sequence (block size 4, intended to equally randomize male and feamle 165 participants). Participants were asked to maintain habitual exercise, meal / diet, and 166 medication / supplement use during the study. The flow of study participants is illustrated in 167 the CONSORT diagram (Supplementary Figure 1). Based on studies of symptoms in older 168 adults [37, 38], we predicted the primary outcome rate in the placebo group will be 169

170	approximately 10%. N=30 (15 per arm) provides 36% power to detect a 25% increase (from
171	10% to 35%) in the proportion of subjects meeting this primary outcome in the KE condition
172	with two-sided α =0.10. If we assume a larger effect of the KE intervention, N = 30 (15 per
173	arm) provides approximately 75% power to detect an increase (from 10% to 55%) in the
174	proportion of subjects meeting this primary outcome in the KE condition, with two-sided
175	α=0.10.

176 2.3

177 Study Beverages

The study KE beverage was a tropical-flavored beverage containing the KE bis-octanoyl (R)-178 1,3-butanediol (Cognitive Switch, BHB Therapeutics Ltd, Dublin, IRE). Each bottle was 75 179 180 mL and contained 25 g of KE. Participants were instructed to consume the study beverage at 181 home daily for 12 weeks within 5 minutes of their first meal of the day. Half of a bottle (12.5 g KE) was consumed daily during week 1, and a full bottle (25 g KE) was consumed daily for 182 the remainder of the study. The placebo used in the study was custom manufactured by BHB 183 184 Therapeutics; the KE was replaced by non-ketogenic canola oil. It was matched for volume, appearance, flavor, and calories. Nutritional facts for study beverages are shown in 185 **Supplementary Table 1**. Beverages were provided as single serving bottles, labeled with the 186 coded group allocation. All personnel involved with the data collection, analysis, and 187 interpretation were blinded to the intervention assigned to participants. Compliance was 188 assessed at week 4 (Visit 4) and week 12 (Visit 5) by asking participants to return any unused 189 product and by review of a daily Study Beverage Log, which was compared to the number of 190 191 unused bottles returned. Participants who consumed between 80 - 120% of their allocated study product were considered compliant. 192

193 **2.4**

194 **Study Questionaires**

195 **2.4.1**

1% Study Beverage Log

The daily Study Beverage Log queried compliance with daily beverage intake. Participants noted if they had consumed the beverage, the time of consumption, and noted if they had experienced any tolerance issues or other adverse events (AE).

200 2.4.2

201 Beverage Tolerability Questionnaire (BTQ)

The BTQ used in this study was similar to that used in previous tolerability studies [34, 39, 202 40]. Ten tolerability issues were included in the BTQ: gas / flatulence, nausea, vomiting, 203 204 abdominal cramping, stomach rumbling, burping, reflux (heartburn), diarrhea, headache, and 205 dizziness. Participants were either asked if the issue occurred since they took the study beverage (paper questionnaire completed daily 3-6 h after KE consumption during 2-week 206 acclimation period) or during the last two weeks (completed verbally during bi-weekly 207 telephone call), and asked to rank the intensity as none, mild (awareness of symptoms but 208 easily tolerated), moderate (discomfort enough to interfere with but not prevent daily activity) 209 or severe (unable to perform usual activity). These correspond to scores of 0-3 respectively 210 211 for each issue, giving a maximal composite score of 30. After acclimation, participants were asked to report the number of days that each symptom occurred at the respective severity. 212

213 **2.5**

214 In-Clinic Procedures

For testing visits on Days 0, ~28, and ~84 (Visits 3, 4, and 5, respectively), participants reported to the clinic after an overnight fast and having avoided exercise, alcohol, and psychoactive cannabis products for at least 10 h. On arrival, fasted blood and urine samples were collected and processed for analysis, including hematology, chemistries, liver function tests, thyroid function tests, and urinalysis. Vital signs (heart rate, seated and standing blood

220	pressure), and body anthropometrics (height, weight, waist circumference) were assessed
221	after the participant had been at rest. Cognitive and physical function were assessd, and
222	quality of life questionnaires were administered during Visits 3 and 5; as these results will be
223	described separately, detailed procedures are not described here, but can be found in the
224	detailed description of the protocol [36].

225	2.6
ZZJ	 .u

226 At-Home Procedures

Each day, at home, participants consumed their regular first meal of the day and consumed the study beverage within 5 minutes of finishing their meal. Participants were asked to complete the BTQ 3-6 hours after consumption of the study beverage.

230 2.7 Study Outcomes

231 **2.7.1**

232 **Primary outcome**

The primary outcome of the BIKE Study was tolerability of the KE intervention, assessed 233 using the BTQ. Specifically, the prespecified primary outcome was the proportion of 234 participants reporting the same moderate to severe symptom (among dizziness, headache, or 235 236 nausea) occurring on more than one day within any given two week recall period (after week 0-2 acclimation period) during a phone interview. Headache, nausea, and dizziness were 237 selected as they occurred significantly more often at mild severity in our previous 28-day 238 239 study of a KE in healthy younger adults [34]. The 'moderate to severe' intensity was selected 240 as 'mild' symptoms are common in this population [37], and may be acceptable if they are 241 outweighed by benefits of the intervention. Moderate to severe symptoms are less common [38] and more likely to be detrimental to quality of life or function. The frequency of 'more 242 than one day per period' is used to reduce the impact of idiosyncratic symptoms on the 243 analysis given the common occurrence of such symptoms in the target population. 244

245 **2.7.2**

246 Secondary outcomes

The secondary outcome of the BIKE Study was safety, assessed through changes over time in clinical and laboratory measures throughout the study, within each group. Changes in body weight, waist circumference, heart rate, systolic and diastolic blood pressure, and orthostatic changes in blood pressure were followed at the last three study visits. The key safety outcome is the within-group change in safety blood parameters. The occurrence of adverse events was also tabulated.

253 **2.8**

254 Biological Sample Analysis

All blood and urine sample analysis for clinical laboratory measures took place at accredited 255 Quest Diagnostics laboratories in California. The clinical chemistry profile included albumin, 256 alkaline phosphatase, alanine transaminase (ALT), aspartate aminotransferase (AST), total 257 258 bilirubin, blood urea nitrogen, creatinine with glomerular filtration rate, carbon dioxide, chloride, globulin, glucose, potassium, total protein, and sodium. A standard lipid panel was 259performed, including total cholesterol, high density lipoprotein (HDL), low density 260 lipoprotein (LDL), non HDL cholesterol, and triglycerides. High-sensitivity C-reactive 261 protein and a thyroid panel, including triiodothyronine uptake, total thyroxine (T4), and free 262 T4 index were measured. The hematology profile included white blood cell count, red blood 263 cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin 264 concentration, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelet 265 count. Urinalysis parameters included glucose, urobilinogen, ketone body, protein, blood 266 cells, bilirubin, specific gravity, and pH. Normal ranges for all values were provided by the 267 analytical lab and accounted for age and gender. 268

269 **2.9**

270 Statistical Methods

271 All analyses were based on intention to treat and were conducted by a blinded external study statistician. The proportion of participants reporting at least 2 occurrences of the target 272 symptoms in the phone interview during the post acclimation period (week 3 onward) was 273 estimated along with an exact 90% confidence interval (CI) within each group and compared 274 between groups with the Fisher's exact test. Additionally, the 10-item composite score, 275 defined as the sum of the respective items, was analyzed with a repeated measures model 276 with an unstructured covariance structured imposed upon the residuals. The frequency of 277 278 each individual symptom was described with counts and percentages overall and by symptom severity for the 14-day acclimitation period (using the daily logs) and in the post acclimitation 279 period (using the phone interview). During the 14-day acclimation period, due to the number 280 of no symptom resposnes, the 3-item (dizziness, headache nausea, maximum score 63) and 281 10-item (maximum score 210) weekly composite score was calculated as the sum of the 282 individual items each day and compared between group with the Wilcoxon rank sum test. 283 Additionally, the within-group change in safety labs, from baseline to each of the interim and 284 final timepoints, was compared between groups with a Wilcoxon rank sum test and a false 285 discovery rate adjustment to control for multiple comparisons. 286

The intent-to-treat (ITT) population comprised data for all participants who were randomized and consumed one serving of the study beverage and was the primary population used to assess safety and tolerability. Additionally, the population of completers was analyzed. Missing data was not imputed.

- 291 **3.0**
- 292 **Results**
- 293 **3.1**

294 **Participants and completion**

295	Participant anthropometric characteristics at baseline are shown in Table 1. A total of 30
296	participants were randomized; 1 participant completed the acute kinetics visit but did not start
297	the main study without giving a reason, and 6 participants dropped out after Day 0 and did
298	not complete the full protocol (KE $n= 2$ (2F), PLA $n = 4$ (3F, 1M)). The reasons and times of
299	withdrawal were as follows: GI issues (KE $n = 2$, week 3 and 5, one participant self-
300	withdrew, one participant withdrawn by medical officer; PLA $n = 1$, week 4, participant
301	withdrew), tiredness (PLA $n = 2$, week 2 and 6, both participants self-withdrew), and
302	increased cholesterol in safety labs (PLA n = 1, week 4, withdrawn by medical officer). The
303	analysis population ($n = 29$) consisted of all participants who started the main study, a
304	CONSORT diagram is shown in Supplemental Figure 1.
305	Adherance with consumption of the study products for the overall population was high, with
306	n = 15 reporting 100% adherance and a range of 94 – 99 % for the remaining 8 participants
307	who completed the study, based on study logs and returned bottles.
308	3.2
309	Tolerance

There was no evidence to support that there was a difference between groups in the study 310 primary end point: the proportion of participants experiencing moderate or severe dizziness, 311 nausea, or headache on more than one day during any of the two-week post-acclimation time 312 periods (Table 2). Similarly, there was no evidence of a difference between groups in the 313 proportion of participants reporting any of the 10 items at moderate or severe intensity on 314 more than one day in any of the two-week post acclimation periods. 315 Other tolerance analyses were exploratory in nature and focused on temporal changes 316 317 through the study, and on other symptom types and severity. The first two weeks of the

intervention was an acclimation period, where serving size increased from 12.5 to 25 g from

319	Day 8 onwards, and participants completed a tolerance questionnaire every day. During this
320	acclimation period $n = 5$ participants (KE = 1, PLA = 4) experienced no symptoms at any
321	time, $n = 8$ participants reported at least one 'mild' symptom (KE = 5, PLA = 3), $n = 13$
322	participants reported at least one 'moderate' symptoms (KE = 6, PLA = 7), and $n = 3$
323	participants experienced one 'severe' symptoms (KE = 2, dizziness on day 6, dizziness on
324	day 14; $PLA = 1$, headache on day 7).
325	As there was a high rate of 'no' symptom reports each day for both groups, three (dizziness,
326	headache and nausea) and ten item composite scores for the tolerance questionnaire were
327	calculated as the total of all scores on days 1-7 (week 1 composite) and $8-14$ (week 2
328	composite) (Table 2). There was no difference between groups in the week 1 composite for
329	the three major symptom items ($p = 0.67$), or in the week 1 composite score for all ten
330	symptom items ($p = 0.38$, Figure 2A). In the second week, when study product serving size
331	increased, there was no difference in the week 2 composite score for the three major items (p
332	= 0.42), but there was a significantly greater week 2 composite score for all ten items in the
333	KE group compared with the PLA group ($p = 0.037$, Figure 3A). When the 14-day
334	acclimation period was considered overall, (day 1 -14 composite), there was no difference in
335	the three-item composite score ($p = 0.43$, Table 2). However, a significant difference was
336	suggested in the distribution of the ten item composite, where the KE group tended higher
337	(median $(25^{\text{th}}, 75^{\text{th}} \text{ percentile } (\text{KE} = 11.5 (3, 28); \text{PLA} = 4 (0, 13) \text{ p} = 0.091).$
338	In the post-acclimation period between $3 - 12$ weeks (Table 2) participants continued to
339	consume the 25 g serving size, but tolerance was assessed less frequently - every 2 weeks -
340	by interview and referral to the daily study log where symptoms could be recorded. There
341	was no main effect of group on the ten-item tolerance score ($p = 0.20$, Figure 2B), a
342	composite of all reported symptoms at their maximum severity, and no group x time

interaction (p = 0.89), or time (p = 0.36). No post hoc testing was performed due to the

³⁴⁴ absence of an interaction effect.

345	In parallel to our primary outcome which focused on moderate to severe symptoms, we also
346	analyzed the proportion of participants who experienced mild dizziness, nausea, or headache
347	at least twice in a two-week period, post acclimation. This was not different between groups.
348	The proportion of participants who reported any of the ten items at least twice at a mild
349	intensity in a two-week period, post acclimation, was also not different between groups.
350	When all symptoms were considered, the most common symptoms reported at least once
351	during acclimation were abdominal cramping $(n = 5)$ and burping $(n = 5)$, and post
352	acclimation were abdominal cramping $(n = 6)$ and reflux $(n = 6)$ for the KE group.
353	Overall, it appeared that up to 25 g of KE taken daily did not meaningfully increase the
354	occurrence of either the expected symptoms based on younger adult studies (dizziness,
355	nausea, or headache), or other symptoms not previously linked to KE consumption.

356 **3.3**

357 Safety

Consumption of up to 25 g per day of KE or PLA by older adults was not associated with any 358 statistically significant or clinically relevant changes in vital signs (Table 3) or any of the 359 laboratory tests conducted: clinical chemistry, hematology, lipid panel, thyroid panel, or 360 urinalysis; selected laboratory values that were expected to be affected by KE metabolism are 361 shown in **Table 3**; all were unchanged. As described above, two participants dropped out of 362 the KE group due to GI issues, compared to four participants dropping out of the placebo 363 group; all dropouts were judged to be at least 'possibly' related to the study products. There 364 were no study product related AEs reported during the study. Seven participants in total 365 reported non-related AEs including: twisted ankle, upper respiratory tract infection (n = 3), 366 367 broken toe, hairline foot fracture, and back pain.

368 **4.0**

369 **Discussion**

The results of this study demonstrate that healthy older adults can tolerably and safely consume up to 25 g per day of the ketone ester, bis-octanoyl-(R)1-3, butanediol. These findings considerably extend the duration of previous KE tolerance and safety studies, as well as provide the first data exclusively in older adults. This establishes a critical platform for future studies investigating exogenous ketones and ketone esters as a geroscience intervention, addressing age-related disease by targeting aging biology.

Despite previous studies of KE finding good adherence, limited symptoms, and no 376 safety concerns, exogenous ketones have a reputation for being difficult to implement in long 377 term interventions [41]. Acute side-effects of a similar nature to those seen in this study (i.e., 378 nausea, headache, dizziness) have been seen with all types of exogenous ketones products that 379 are functionally similar to BO-BD, including medium chain triglycerides (MCT), 1,3-380 butanediol, ketone salts, acetoacetate ketone di-ester, and BHB-ketone mono-ester [42-45]. 381 These side-effects are seen at a range of serving sizes (10 - 85g), under different conditions 382 (fed, fasted, rest, exercise), and manifest as both acute GI discomfort and distress, as well as 383 systemic symptoms such as headache, nausea, and dizziness that range in frequency and 384 385 intensity from mild to severe. In the current study, symptoms occurred at a similar rate in both ketone ester and placebo groups, and symptoms were not more frequent than seen in studies of 386 BH-BD or BO-BD in younger adults [11, 34], despite the expectation that older adults might 387 have either an increased risk of intervention-related symptoms or an increased rate of non-388 related, sporadic symptoms. Overall, these data support the conclusion that BO-BD is well 389 tolerated in healthy older adults at the serving sizes studied. 390

Alongside tolerance, an often cited concern with longer term studies of ketone esters is lack of adherence due to poor palatability [41], leading investigators to compare product palatability as an important component of intervention selection [46]. In a recent study, the

sensory characteristics of BO-BD to BH-BD were compared and found BO-BD was more
palatable [11]. In the current study, the high adherence rate of participants indicates that this
KE was acceptable, and that palatability issues would not be a barrier to longer term
implementation.

A final area of concern is safety of long-term KE consumption, which was a key 398 endpoint of this study given the expected vulnerability of the older adult population. Based on 399 previous studies of exogenous ketones, there were several areas that were carefully monitored 400 here. Firstly, as KE have previously been seen to suppress appetite [47], which would be 401 undesirable in an older population, we monitored body weight and saw no change in either 402 group. Secondly, as the KE is a lipid-based molecule that is metabolized in the liver and the 403 canola oil placebo contained lipids, we closely tracked changes to lipid panels (withdrawing 404one participant in the PLA group) and liver function tests. No changes in these lab tests were 405 deemed clinically significant by the independent study medical officers. Thirdly, exogenous 406 ketones can acutely alter blood acid-base balance and electrolytes [48] which could be 407 problematic either in isolation or via medication interactions; no changes were seen in related 408 endpoints here. Finally, we monitored vital signs, as exogenous ketones have been 409 demonstrated to acutely increase heart rate and decrease blood pressure [49]; these were again 410 unchanged in this study. Notably, we did not see changes in fasting glucose in either group; a 411 decrease in glucose might have been expected in the KE group given the consistent 412 hypoglycemic effect of exogenous ketones [19]. Overall, in this relatively healthy population 413 of older adults, 25 g of KE daily for 12 weeks did not lead to any safety concerns. Still, safety 414 monitoring should remain a key feature of future geroscience studies using ketone esters, as 415 less healthy populations or populations with specific comorbidities may be more vulnerable to 416 metabolic and physiologic perturbation. 417

Given that there were no tolerance, safety, or compliance concerns raised by this 418 study, increased KE dosing could be considered in future work. Up to 50 g/day for one week 419 of BO-BD per day has been studied in younger adults [11], and servings of up to 75 g /day for 420 28 days of other KE has been reported [32, 33]. As we saw symptoms increase with increasing 421 dose between days 8 - 14 and then decline over the remainder of the study, we suggest that 422 gradually increasing the daily serving over several weeks may provide optimal tolerance. This 423 would be consistent with the gradually increasing serving size recommended in clinical 424 protocols for MCT use in therapeutic ketogenic diets [50]. The advantage of providing a 425 higher dose, split into multiple servings across the day, would be an increased time in a state 426 of hyper-ketonemia. It is currently unknown if greater peak ketone concentrations or greater 427 time of ketone exposure time drives clinical efficacy. Studies that have found benefits of 428 exogenous ketones in metabolic [19], cardiac [49], and cognitive [51] function have linked 429 blood ketone concentration to improved efficacy. These observations reinforce the need to use 430 the maximal tolerable and safe dose in studies designed to explore new applications of 431 nutritional ketosis. 432

The strengths of this study include the free-living, pragmatic-inspired design (e.g. 433 participants were instructed to maintain their usual diet and exercise habits) being highly 434 relevant for future uses of KE as a geroscience intervention, the high adherence observed, the 435 equal enrollment of men and women, the average age (76 y) being well over the lower limit 436 (65 y), and the close matching achieved between the KE and PLA beverage. The weaknesses 437 of this study were to be expected, given that it was planned as a pilot to help design a larger 438 clinical trial targeting physical function related to frailty in older adults. Firstly, the sample 439 size was small, and predominantly identified as non-Hispanic white; results in this population 440 may not be generalizable to larger studies or to all populations of older adults. Secondly, the 441 overall incidence of dropouts was 23%, slightly higher than our expected 20%, but this rate 442

decreases if accounting for the participant who was randomized but did not start the 12-week 443 study, and more participants in the PLA group did not complete the study compared to the KE 444group. Thirdly, we relied on beverage logs and bottle return to confirm compliance but there is 445 not a validated biomarker that allows us to verify that beverage consumption was accurately 446 reported. Finally, although we encouraged participants to use the beverage log to record any 447 symptoms in their daily log, they did not have to complete a full questionnaire every day after 448 day 14, meaning some symptoms may have been forgotten and not reported. We expect that 449 this effect might be more relevant to mild symptoms, as moderate and severe symptoms would 450 be more disruptive and more likely to be remembered and reported. 451

In conclusion this pilot study demonstrated the safety and tolerability of 12-weeks of consumption of up to 25 g per day of the ketone di-ester, bis-octanoyl-(R)-1,3-butanediol in healthy older adults. These findings will facilitate the application of ketone body biology in human health and disease in aging.

456 Sources of Funding:

Funding for the study was provided by philanthropic donations from Dr. James B. Johnson and from members of the Buck Institute Impact Circle. Dr. Johnson assisted with conceptualization of the study and reviewed this manuscript but has no further role in study design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications. The Buck Institute Impact Circle had no role in conceptualization, study design, management, data collection, analysis, interpretation of data, decision to submit publications, review, or writing of publications.

⁴⁶⁴ Dr. Newman's participation in the study was supported by Buck Institute institutional funds.

Dr. Brianna Stubbs' participation in the study was supported by the NIH (NIA) under award
 number K01AG078125.

The KE intervention was provided gratis by BHB Therapeutics Ltd (Ireland). BHB Therapeutics also arranged for manufacture of the matched placebo, paid for by study funds. BHB Therapeutics (Ireland) markets formulated KE beverages to consumers. BHB Therapeutics (Ireland) provided no funding for the study, and had no role in the design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications.

473 Author Declarations and Conflict Management:

The Buck Institute holds shares in BHB Therapeutics (Ireland) and Selah Therapeutics. B.J.S. has stock in H.V.M.N Inc, and stock options in Selah Therapeutics Ltd, BHB Therapeutics (Ireland) Ltd., and Juvenescence Ltd. J.C.N. has stock options in Selah Therapeutics Ltd and BHB Therapeutics (Ireland) Ltd. J.C.N and B.J.S. are inventors on patents related to the use of ketone bodies that are assigned to The Buck Institute. Individual and institutional conflict management plans were developed and approved by the Buck Institute and submitted to the reviewing IRB. Actions and decisions important to participant safety and study integrity were

carried out by 'honest brokers' with no potential financial conflict. Participant consent was obtained by licensed registered nurses (L.A and W.S.M) who have no financial conflict. Decisions on participant enrollment, continuation, and were made by independent medical officers (J.M and M.Y) unaffiliated with Buck Institute and with no financial conflict. Data analysis for the primary outcome was carried out by an independent statistician with no financial conflict (T.B). All other authors have no conflicts to report.

- 487 Author Contributions: Conceptualization, J.C.N, B.J.S; methodology, J.C.N, B.J.S;
- investigation, B.J.S, E.B.S, C.S, S.R.D, S.P, W.S-M, L.A, M.Y, J.M; data curation, B.J.S,
- 489 E.B.S, C.S, S.R.D, S.P; formal analysis, T.B, B.J.S; writing—original draft preparation, B.J.S,
- 490 E.B.S; writing-review and editing, all; visualization, B.J.S, T.B; project administration,
- ⁴⁹¹ B.J.S, J.C.N, T.G; supervision: B.J.S, T.G, J.C.N; funding acquisition, B.J.S, J.C.N; All
- ⁴⁹² authors have read and agreed to the published version of the manuscript.

493 Data Availability Statement: The data presented here may be available upon reasonable
 494 request from the corresponding author and in accordance with intellectual property
 495 considerations.

496		Reference List
497 498 499 500	[1]	C. L. Green, D. W. Lamming, and L. Fontana, "Molecular mechanisms of dietary restriction promoting health and longevity," <i>Nat. Rev. Mol. Cell Biol.</i> , vol. 23, no. 1, pp. 56-73, Jan 2022, doi: 10.1038/s41580-021-00411-4.
501 502 503	[2]	A. D. Rickman <i>et al.</i> , "The CALERIE Study: design and methods of an innovative 25% caloric restriction intervention," <i>Contemp. Clin. Trials</i> , vol. 32, no. 6, pp. 874-81, Nov 2011, doi: 10.1016/j.cct.2011.07.002.
504 505 506 507	[3]	J. C. Newman, S. Milman, S. K. Hashmi, S. N. Austad, J. L. Kirkland, J. B. Halter, and N. Barzilai, "Strategies and Challenges in Clinical Trials Targeting Human Aging," <i>J. Gerontol. A Biol. Sci. Med. Sci.</i> , vol. 71, no. 11, pp. 1424-1434, Nov 2016, doi: 10.1093/gerona/glw149.
508 509 510	[4]	J. Justice <i>et al.</i> , "Frameworks for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging Processes," <i>J. Gerontol. A Biol. Sci. Med. Sci.</i> , vol. 71, no. 11, pp. 1415-1423, Nov 2016, doi: 10.1093/gerona/glw126.
511 512	[5]	G. F. Cahill, Jr., "Fuel metabolism in starvation," (in English), Annual Review of Nutrition, Review vol. 26, pp. 1-22, 2006.
513 514	[6]	G. Reichard Jr, O. Owen, A. Haff, P. Paul, and W. Bortz, "Ketone-body production and oxidation in fasting obese humans," <i>J. Clin. Invest.</i> , vol. 53, no. 2, p. 508, 1974.
515 516 517	[7]	J. C. Newman and E. Verdin, "beta-Hydroxybutyrate: A Signaling Metabolite," (in eng), <i>Annual review of nutrition</i> , vol. 37, pp. 51-76, Aug 21 2017, doi: 10.1146/annurev-nutr-071816-064916.
518 519 520	[8]	M. N. Roberts <i>et al.</i> , "A Ketogenic Diet Extends Longevity and Healthspan in Adult Mice," <i>Cell Metabolism</i> , vol. 26, no. 3, pp. 539-546.e5, 2017, doi: 10.1016/j.cmet.2017.08.005.
521 522 523	[9]	J. C. Newman <i>et al.</i> , "Ketogenic Diet Reduces Midlife Mortality and Improves Memory in Aging Mice," (in eng), <i>Cell metabolism</i> , vol. 26, no. 3, pp. 547-557.e8, 2017, doi: 10.1016/j.cmet.2017.08.004.
524 525 526 527	[10]	C. D. Crabtree <i>et al.</i> , "Bis Hexanoyl (R)-1,3-Butanediol, a Novel Ketogenic Ester, Acutely Increases Circulating r- and s-ss-Hydroxybutyrate Concentrations in Healthy Adults," <i>J Am Nutr Assoc</i> , pp. 1-9, Mar 25 2022, doi: 10.1080/07315724.2021.2015476.
528 529 530 531	[11]	B. J. Stubbs <i>et al.</i> , "A randomized, open-label, cross-over pilot study investigating metabolic product kinetics of the palatable novel ketone ester, bis-octanoyl (R)-1,3-butanediol, and bis-hexanoyl (R)-1,3-butanediol ingestion in healthy adults," <i>Toxicology Research</i> , 2023 (submitted).

- B. J. Stubbs *et al.*, "In vitro stability and in vivo pharmacokinetics of the novel ketogenic ester, bis hexanoyl (R)-1,3-butanediol," (in eng), *Food Chem. Toxicol.*, vol. 147, p. 111859, Jan 2021, doi: 10.1016/j.fct.2020.111859.
- ⁵³⁵ [13] A. P. Koutnik *et al.*, "Ketone Bodies Attenuate Wasting in Models of Atrophy," (in ⁵³⁶ eng), *J Cachexia Sarcopenia Muscle*, Apr 2 2020, doi: 10.1002/jcsm.12554.
- A. P. Koutnik, D. P. D'Agostino, and B. Egan, "Anticatabolic Effects of Ketone Bodies in Skeletal Muscle," *Trends Endocrinol. Metab.*, vol. 30, no. 4, pp. 227-229, Apr 2019, doi: 10.1016/j.tem.2019.01.006.
- S. R. Yurista *et al.*, "Ketone Ester Treatment Improves Cardiac Function and Reduces
 Pathologic Remodeling in Preclinical Models of Heart Failure," *Circ. Heart Fail.*, vol.
 14, no. 1, p. e007684, Jan 2021, doi: 10.1161/CIRCHEARTFAILURE.120.007684.
- 543 [16] J. L. Horton *et al.*, "The failing heart utilizes 3-hydroxybutyrate as a metabolic stress
 544 defense," (in eng), *JCI Insight*, vol. 4, no. 4, Feb 21 2019, doi:
 545 10.1172/jci.insight.124079.
- Q. Y. Ang *et al.*, "Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells," (in eng), *Cell*, vol. 181, no. 6, pp. 1263-1275.e16, Jun 11 2020, doi: 10.1016/j.cell.2020.04.027.
- E. L. Goldberg, R. D. Molony, E. Kudo, S. Sidorov, Y. Kong, V. D. Dixit, and A.
 Iwasaki, "Ketogenic diet activates protective γδ T cell responses against influenza virus infection," (in eng), *Sci Immunol*, vol. 4, no. 41, Nov 15 2019, doi: 10.1126/sciimmunol.aav2026.
- [19] K. Falkenhain, A. Daraei, S. C. Forbes, and J. P. Little, "Effects of Exogenous Ketone
 Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis," *Adv Nutr*, Apr 5 2022, doi: 10.1093/advances/nmac036.
- G. Greaves, R. Xiang, H. Rafiei, A. Malas, and J. P. Little, "Prior ingestion of a ketone monoester supplement reduces postprandial glycemic responses in young healthy-weight individuals," *Appl Physiol Nutr Metab*, vol. 46, no. 4, pp. 309-317, Apr 2021, doi: 10.1139/apnm-2020-0644.
- É. Myette-Côté, H. G. Caldwell, P. N. Ainslie, K. Clarke, and J. P. Little, "A ketone monoester drink reduces the glycemic response to an oral glucose challenge in individuals with obesity: a randomized trial," *The American Journal of Clinical Nutrition*, vol. 110, no. 6, pp. 1491-1501, 2019, doi: 10.1093/ajcn/nqz232.
- E. Myette-Cote, H. Neudorf, H. Rafiei, K. Clarke, and J. P. Little, "Prior ingestion of
 exogenous ketone monoester attenuates the glycaemic response to an oral glucose
 tolerance test in healthy young individuals," (in eng), *J. Physiol.*, vol. 596, no. 8, pp.
 1385-1395, Apr 15 2018, doi: 10.1113/JP275709.

- P. J. Cox *et al.*, "Nutritional Ketosis Alters Fuel Preference and Thereby Endurance
 Performance in Athletes," *Cell Metabolism*, vol. 24, pp. 1-13, 9th August 2016 2016,
 doi: 10.1016/j.cmet.2016.07.010.
- [24] C. Poffe, M. Ramaekers, S. Bogaerts, and P. Hespel, "Bicarbonate Unlocks the 571 Ergogenic Action of Ketone Monoester Intake in Endurance Exercise," Med Sci 572 Exerc. vol. 431-441, Feb Sports 53. no. 2. pp. 1 2021, doi: 573 10.1249/MSS.00000000002467. 574
- 575 [25] C. Poffe, M. Ramaekers, R. Van Thienen, and P. Hespel, "Ketone ester supplementation blunts overreaching symptoms during endurance training overload," *J. Physiol.*, vol. 597, no. 12, pp. 3009-3027, Jun 2019, doi: 10.1113/JP277831.
- K. Coleman, J. Phillips, M. Sciarini, B. Stubbs, O. Jackson, and D. Kernagis, "A
 Metabolic Intervention for Improving Human Cognitive Performance During
 Hypoxia," *Aerospace medicine and human performance*, vol. 92, no. 7, pp. 556-562,
 Jul 1 2021, doi: 10.3357/AMHP.5767.2021.
- M. Evans and B. Egan, "Intermittent Running and Cognitive Performance after Ketone Ester Ingestion," (in eng), *Med Sci Sports Exerc*, vol. 50, no. 11, pp. 2330-2338, Nov 2018, doi: 10.1249/MSS.00000000001700.
- J. J. Walsh, H. G. Caldwell, H. Neudorf, P. N. Ainslie, and J. P. Little, "Short-term ketone monoester supplementation improves cerebral blood flow and cognition in obesity: A randomized cross-over trial," *J. Physiol.*, vol. 599, no. 21, pp. 4763-4778, Nov 2021, doi: 10.1113/JP281988.
- [29] H. Neudorf, É. Myette-Côté, and J. P. Little, "The Impact of Acute Ingestion of a Ketone Monoester Drink on LPS-Stimulated NLRP3 Activation in Humans with Obesity," *Nutrients*, vol. 12, no. 3, 2020, doi: 10.3390/nu12030854.
- [30] S. Selvaraj *et al.*, "Acute Echocardiographic Effects of Exogenous Ketone
 Administration in Healthy Participants," *J. Am. Soc. Echocardiogr.*, vol. 35, no. 3, pp.
 305-311, Mar 2022, doi: 10.1016/j.echo.2021.10.017.
- [31] H. J. Beijer and C. J. de Blaey, "Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies," *Pharm. World Sci.*, vol. 24, no. 2, pp. 46-54, Apr 2002, doi: 10.1023/a:1015570104121.
- [32] A. Soto-Mota, H. Vansant, R. D. Evans, and K. Clarke, "Safety and tolerability of sustained exogenous ketosis using ketone monoester drinks for 28 days in healthy adults," (in eng), *Regul. Toxicol. Pharmacol.*, vol. 109, p. 104506, Dec 2019, doi: 10.1016/j.yrtph.2019.104506.
- [33] A. Soto□Mota, N. G. Norwitz, R. Evans, K. Clarke, and T. M. Barber, "Exogenous ketosis in patients with type 2 diabetes: Safety, tolerability and effect on glycaemic control," *Endocrinology, Diabetes & Metabolism,* 2021, doi: 10.1002/edm2.264.

- 605 [34] O. Chen *et al.*, "Tolerability and Safety of a Novel Ketogenic Ester, Bis-Hexanoyl
 606 (R)-1,3-Butanediol: A Randomized Controlled Trial in Healthy Adults," *Nutrients*,
 607 vol. 13, no. 6, Jun 16 2021, doi: 10.3390/nu13062066.
- E. B. Stephens *et al.*, "A randomized open-label, observational study of the novel ketone ester, bis octanoyl (R)-1,3-butanediol, and its acute effect on β-hydroxybutyrate and glucose concentrations in healthy older adults," *medRxiv*, April 18, 2024 2024, doi: 10.1101/2024.04.16.24305925.
- B. J. Stubbs *et al.*, "Rationale and protocol for a safety, tolerability and feasibility randomized, parallel group, double-blind, placebo-controlled, pilot study of a novel ketone ester targeting frailty via immunometabolic geroscience mechanisms (Preprint)," *MedRxiv*, 2023, doi: 10.1101/2023.10.25.23297571.
- [37] M. A. Han, M. E. Tinetti, J. V. Agostini, L. Han, H. Lee, and L. M. Walke, "The impact of medication use on symptom burden in older patients with multiple medical morbidities," *Journal of Clinical Gerontology and Geriatrics*, vol. 4, no. 3, pp. 84-88, 2013, doi: 10.1016/j.jcgg.2013.03.002.
- S. I. Chaudhry, T. E. Murphy, E. Gahbauer, L. S. Sussman, H. G. Allore, and T. M. [38] 620 Gill, "Restricting symptoms in the last year of life: a prospective cohort study," JAMA 621 1534-40, Sep Intern Med, vol. 173, no. 16, pp. 9 2013, doi: 622 10.1001/jamainternmed.2013.8732. 623
- K. C. Maki, T. M. Rains, K. M. Kelley, C. M. Cook, A. L. Schild, and E. Gietl,
 "Fibermalt is well tolerated in healthy men and women at intakes up to 60 g/d: a
 randomized, double-blind, crossover trial," *Int. J. Food Sci. Nutr.*, vol. 64, no. 3, pp.
 274-81, May 2013, doi: 10.3109/09637486.2012.738652.
- B. M. Boler, M. C. Serao, L. L. Bauer, M. A. Staeger, T. W. Boileau, K. S. Swanson,
 and G. C. Fahey, Jr., "Digestive physiological outcomes related to polydextrose and
 soluble maize fibre consumption by healthy adult men," *Br J Nutr*, vol. 106, no. 12,
 pp. 1864-71, Dec 2011, doi: 10.1017/S0007114511002388.
- [41] S. R. Yurista, C. R. Chong, J. J. Badimon, D. P. Kelly, R. A. de Boer, and B. D.
 Westenbrink, "Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review," *J. Am. Coll. Cardiol.*, vol.
 77, no. 13, pp. 1660-1669, Apr 6 2021, doi: 10.1016/j.jacc.2020.12.065.
- [42] B. J. Stubbs, P. J. Cox, T. Kirk, R. D. Evans, and K. Clarke, "Gastrointestinal Effects of Exogenous Ketone Drinks are Infrequent, Mild, and Vary According to Ketone Compound and Dose," *International journal of sport nutrition and exercise metabolism*, vol. 29, no. 6, pp. 596-603, Nov 1 2019, doi: 10.1123/ijsnem.2019-0014.
- [43] D. M. Shaw, F. Merien, A. Braakhuis, D. Plews, P. Laursen, and D. K. Dulson, "The Effect of 1,3-Butanediol on Cycling Time-Trial Performance," (in English), *International journal of sport nutrition and exercise metabolism*, vol. 29, no. 5, pp. 466-473, Sep 1 2019, doi: 10.1123/ijsnem.2018-0284.

- 644 [44] S. T. Henderson, J. L. Vogel, L. J. Barr, F. Garvin, J. J. Jones, and L. C. Costantini,
 ⁶⁴⁵ "Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a
 ⁶⁴⁶ randomized, double-blind, placebo-controlled, multicenter trial," (in eng), *Nutr Metab*⁶⁴⁷ (*Lond*), vol. 6, p. 31, 2009, doi: 10.1186/1743-7075-6-31.
- [45] J. J. Leckey, M. L. Ross, M. Quod, J. A. Hawley, and L. M. Burke, "Ketone Diester 648 Ingestion Impairs Time-Trial Performance in Professional Cyclists," Front. Physiol., 649 10.3389/fphys.2017.00806 vol. 8, 806, 2017. [Online]. Available: 650 p. https://www.frontiersin.org/article/10.3389/fphys.2017.00806. 651
- [46] K. Falkenhain, A. Daraei, and J. P. Little, "The Effect of Novel Exogenous Ketone
 Supplements on Blood Beta-Hydroxybutyrate and Glucose," *Journal of Dietary Supplements*, pp. 1-15, 2023, doi: 10.1080/19390211.2023.2179152.
- [47] B. J. Stubbs, P. J. Cox, R. D. Evans, M. Cyranka, K. Clarke, and H. de Wet, "A
 Ketone Ester Drink Lowers Human Ghrelin and Appetite," *Obesity*, vol. 26, no. 2, pp.
 269-273, 2018, doi: 10.1002/oby.22051.
- [48] B. J. Stubbs *et al.*, "On the Metabolism of Exogenous Ketones in Humans," *Front. Physiol.*, vol. 8, p. 848, 10/30
- 660 08/22/received
- ⁶⁶¹ 10/11/accepted 2017, doi: 10.3389/fphys.2017.00848.
- R. Nielsen *et al.*, "Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients," *Circulation*, vol. 139, no. 18, pp. 2129-2141, Apr 30 2019, doi: 10.1161/CIRCULATIONAHA.118.036459.
- [50] Y.-m. C. Liu, "Medium-chain triglyceride (MCT) ketogenic therapy," *Epilepsia*, vol. 49, no. s8, pp. 33-36, 2008/11/01 2008, doi: 10.1111/j.1528-1167.2008.01830.x.
- M. Fortier *et al.*, "A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT," *Alzheimer's & dementia : the journal of the Alzheimer's Association*, vol. 17, no. 3, pp. 543-552, Mar 2021, doi: 10.1002/alz.12206.
- 671

	Statistic/Group	Total Enrolled (n=30)	KE (n=15)	PLA (n=15)
Sex	Female	15 (50%)	8 (53.3%)	7 (46.7%)
	Male	15 (50%)	7 (46.7%)	8 (53.3%)
Age (years)	Mean (SD)	76.5 (6.4)	75.2 (5.6)	77.9 (7.0)
	Median (min, max)	75.8 (65.1, 89.8)	75.1 (65.1, 87.3)	76.4 (67.5, 89.8)
Ethnicity	Hispanic/Latino	2 (6.7%)	1 (6.7%)	1 (6.7%)
	Not Hispanic/Latino	28 (93.3%)	14 (93.3%)	14 (93.3%)
Race	Prefer not to say	0 (0%)	0 (0%)	0 (0%)
America	n Indian/Alaskan Native	0 (0%)	0 (0%)	0 (0%)
	Asian	1 (3.3%)	1 (6.7%)	0 (0%)
	Black/African American	0 (0%)	0 (0%)	0 (0%)
Hispanic, L	atinx, or Spanish Origin	2 (6.7%)	1 (6.7%)	1 (6.7%)
Native Hawaiian	or Other Pacific Islander	0 (0%)	0 (0%)	0 (0%)
	Prefer not to say	0 (0%)	0 (0%)	0 (0%)
	Two or more races	0 (0%)	0 (0%)	0 (0%)
	Unknown	0 (0%)	0 (0%)	0 (0%)
	White	27 (90%)	13 (86.7%)	14 (93.3%)
Weight (kg)	Mean (SD)	72.9 (15.8)	70.3 (15.0)	75.6 (16.7)
	Median (min, max)	72.1 (47.8, 101.3)	70.3 (47.8, 101.3)	76.4 (50.5, 99.7)
Height (cm)	Mean (SD)	168.0 (10.8)	166.2 (11.0)	169.8 (10.6)
	Median (min, max)	168.8 (150.0, 189.0)	166.0 (150.0, 188.0)	169.0 (153.0, 189.0)
BMI (kg/m ²)	Mean (SD)	25.2 (3.0)	24.5 (2.2)	25.9 (3.6)
	Median (min, max)	25.8 (19.9, 32.7)	25.0 (21.0, 28.0)	26.7 (19.9, 32.7)
Waist Circumference	Mean (SD)	91.2 (12.2)	88.5 (12.5)	94.0 (11.6)
(cm)	Median (min, max)	92.0 (66.5, 118.0)	88.0 (66.5, 118.0)	98.0 (75.5, 113.0)

Table 1: Study participant characteristics 673

Description of characteristics of randomized study participants. Data represents all 674 individuals' values obtained at their screening visit.

675

Abbreviations: BMI, body mass index; KE, ketone ester; max, maximum; min, minimum; 676

PLA, placebo; SD, standard deviations. 677

Table 2: Tolerance outcomes

			Gr	oup
Time Period	Score	Statistic	PLA	KE
Acclimation				
Day 1 - 7	10-item composite total, max $/210$	Ν	15	14
	(daily scores added)	Mean (SD)	3.9 (6.0)	5.6 (6.6)
		Median (Min, Max)	2.0 (0.0, 22.0)	4.0 (0.0, 23.0)
		P25, P75	0.0, 6.0	0.0, 11.0
		p-value	0.38	
	3-item composite total, max /63	N	15	14
	Dizziness, headache, nausea	Mean (SD)	0.7 (1.8)	0.8 (1.8)
	(daily scores added)	Median (Min, Max)	0.0 (0.0, 6.0)	0.0 (0.0, 6.0)
		P25, P75	0.0, 0.0	0.0, 0.0
		p-value	0.67	
Day 8 - 14	10-item composite total, max /210	N	15	14
•	(daily scores added)	Mean (SD)	4.5 (7.5)	10.6 (11.8)
		Median (Min, Max)	2.0 (0.0, 26.0)	9.0 (0.0, 45.0)
		P25, P75	0.0, 7.0	2.0, 17.0
		p-value	0.037	
	3-item composite total, max /63	N	15	14
	Dizziness, headache, nausea	Mean (SD)	1.3 (3.3)	1.9 (3.9)
	(daily scores added)	Median (Min, Max)	0.0 (0.0, 12.0)	0.0 (0.0, 14.0)
		P25, P75	0.0, 1.0	0.0, 1.0
		p-value	0.42	
14-day TOTAL	10-item composite total, max /420	N	15	14
	(daily scores added)	Mean (SD)	8.4 (12.8)	16.3 (16.2)
		Median (Min, Max)	4.0 (0.0, 48.0)	11.5 (0.0, 56.0)
		P25, P75	0.0, 13.0	3.0, 28.0
		p-value	0.091	
	3-item composite total, max/126	N	15	14
	Dizziness, headache, nausea	Mean (SD)	2.0 (5.1)	2.7 (4.5)
	(daily scores added)	Median (Min, Max)	0.0 (0.0, 18.0)	0.0 (0.0, 14.0)
	· ····································	P25, P75	0.0, 1.0	0.0, 6.0
		p-value	0.43	,
Time Period	Score	Statistic	PLA	KE
Post-acclimation				
Week 3-4	10-item composite, max /30	Ν	14	14
HUCK 5 T	(max severity in 2 wk)	Mean (SD)	0.8 (1.0)	1.9 (2.2)
		Median (Min, Max)	0.5 (0.0, 3.0)	1.0 (0.0, 8.0)
		P25, P75	0.0, 1.0	1.0, 2.0
		Estimate (90% CI)	0.8 (0.0, 1.6)	1.9 (1.1, 2.6)
Week 5-6	10-item composite, max /30	N	13	1.9 (1.1, 2.0)
WEEK J-O	-	Mean (SD)	1.6 (1.8)	1.5 (2.5)
	(max severity in 2 wk)	, , ,	1.0 (0.0, 7.0)	1.0 (0.0, 9.0)
		Median (Min, Max)	1.0 (0.0, 7.0)	1.0 (0.0, 9.0)

			Group				
Time Period	Score	Statistic	PLA	KE			
		Estimate (90% CI)	1.6 (0.4, 2.8)	2.1 (0.9, 3.3)			
Week 7-8	10-item composite, max	N	12	12			
	(max severity in 2 wk)	Mean (SD)	0.4 (0.9)	0.9 (1.2)			
		Median (Min, Max)	0.0 (0.0, 3.0)	1.0 (0.0, 4.0)			
		P25, P75	0.0, 0.5	0.0, 1.0			
		Estimate (90% CI)	0.4 (-0.1, 1.0)	0.8 (0.2, 1.3)			
Week 9-10	10-item composite, max /30	N	11	12			
	(max severity in 2 wk)	Mean (SD)	1.0 (1.7)	1.3 (1.4)			
		Median (Min, Max)	0.0 (0.0, 5.0)	1.5 (0.0, 4.0)			
		P25, P75	0.0, 2.0	0.0, 2.0			
		Estimate (90% CI)	1.2 (0.2, 2.3)	1.9 (0.9, 3.0)			
Week 11-12	10-item composite, max /30	N	11	12			
	(max severity in 2 wk)	Mean (SD)	0.6 (1.6)	1.3 (1.3)			
		Median (Min, Max)	0.0 (0.0, 5.0)	1.0 (0.0, 4.0)			
		P25, P75	0.0, 0.0	0.0, 2.0			
		Estimate (90% CI)	0.7 (-0.2, 1.6)	1.7 (0.8, 2.5)			
Post-acclimation							
Severity	Score	Statistic	PLA	KE			
Mod/Sev, >1 day	3-item (dizziness, headache, nausea) *	No - n (%)	13 (92.9)	12 (85.7)			
		Yes- n (%)	1 (7.1)	2 (14.3)			
		90% CI	0.4, 29.7	2.6, 38.5			
Mod/Sev, >1 day	10-item (any symptom)	No - n (%)	12 (85.7)	11 (78.6)			
		Yes- n (%)	2 (14.3)	3 (21.4)			
		90% CI	2.6, 38.5	6.1, 46.6			
Mild, >1 day	3-item (dizziness, headache, nausea)	No - n (%)	12 (85.7)	10 (71.4)			
		Yes- n (%)	2 (14.3)	4 (28.6)			
		90% CI	2.6, 38.5	10.4, 54.0			
Mild, >1 day	10-item (any symptom)	No - n (%)	7 (50.0)	4 (28.6)			
		Yes- n (%)	7 (50.0)	10 (71.4)			
		90% CI	26.4, 73.6	46.0, 89.6			

⁶⁸⁰ Tolerance data for healthy older adults consuming ketone ester or placebo daily for 12 weeks.

⁶⁸¹ Data is shown for the acclimation period, where serving was escalated from 12.5 to 25 g

daily (assessed by daily questionnaire), and for the 10 weeks post acclimation (assessed in bi-

weekly phone interview). Data is shown for all 10 items on the beverage tolerance

questionnaire as well as the 3 pre-selected items of interest (dizziness, nausea, headache).

⁶⁸⁵ Proportion of participants with mild OR moderate/severe symptoms on more than one day is

show; the primary study outcome is indicated with *. Abbreviations: CI, confidence

interval; Mod, moderate; Sev, severe, PLA, placebo; KE, ketone ester.

All data are 'all reported' at each time point.

			BL			W4		,	W12			ΔBI	_ vs W			ΔBL v	s W12	
		Mean	SD	Ν	Mean	SD	Ν	Mean	SD	Ν	Mean	SD	N	KE vs PLA p value	Mean	SD	Ν	KE vs PLA p value
Vital signs		meun	50		Weun	50	11	Weath	50	11	Weath	50	11	p vulue	Witten	50	11	praide
Resting HR	KE	69.1	13.3	14	65.4	12.6	14	71.9	12.7	12	-3.6	10.0	14	*0.0386	3.5	8.8	12	0.4955
(BPM)	PLA	64.3	6.0	15	67.6	9.1	14	65.6	9.5	11	3.0	7.4	14		0.9	5.7	11	
Weight	KE	71.4	14.2	14	71.9	14.7	14	69.5	12.1	11	0.5	1.0	14	0.1821	0.8	2.0	11	0.1105
(kg)	PLA	75.7	16.8	15	76.9	16.1	14	78.3	17.4	11	-0.2	1.3	14		0.1	1.1	11	
Waist Circumference	KE	90.6	13.7	14	91.5	12.5	13	87.9	11.4	12	0.0	3.9	13	0.8403	-0.8	2.7	12	0.9538
(cm)	PLA	92.9	13.2	15	94.8	11.9	14	93.5	11.5	11	0.4	5.8	14		-0.6	4.0	11	
Seated Systolic BP	KE	132.9	18.7	14	135.2	28.8	14	140.7	17.0	12	2.3	20.9	14	0.4619	5.6	16.6	12	0.9844
(mmHg)	PLA	132.7	15.0	15	130.4	13.6	14	138.4	16.5	11	-2.5	13.5	14		3.2	14.8	11	
Seated Diastolic BP	KE	78.4	11.9	14	73.7	11.4	14	80.1	9.4	12	-4.7	7.6	14	0.2052	0.4	7.7	12	0.2781
(mmHg)	PLA	78.1	7.2	15	78.5	11.3	14	82.8	11.0	11	-0.4	10.9	14		3.1	8.0	11	
Standing Systolic BP	KE	121.8	19.2	14	127.7	24.5	14	127.6	20.5	12	5.9	12.3	14	0.6651	3.4	11.2	12	0.7605
(mmHg)	PLA	123.7	14.7	15	128.2	20.6	14	131.0	18.5	11	3.7	15.1	14		4.0	13.8	11	
Standing Diastolic BP	KE	72.6	10.0	14	74.4	13.5	14	71.7	10.1	12	1.8	7.5	14	0.4017	-1.5	6.9	12	0.0535
(mmHg)	PLA	72.7	7.6	15	77.4	11.7	14	78.8	9.1	11	4.5	11.6	14		4.4	6.0	11	
Selected safety labs																		
			BL			W4			W12			ΔBI	L vs W	4		ΔBL v	s W12	
		Mean	SD	Ν	FDR				FDR									
LDL	KE	98	26	14	89	23	14	99	24	12	-6.9	16.9	14	0.93	-5.9	18.6	12	0.93
	PLA	97	27	15	91	33	14	89	23	11	-5.0	24.5	14		-4.4	10.9	11	
Total Cholesterol	KE	194	33	14	181	29	14	194	36	12	-9.5	18.0	14	0.88	-5.2	21.9	12	0.83
	PLA	179	35	15	175	46	14	171	31	11	-1.6	29.3	14		-0.6	14.4	11	
Triglycerides	KE	70	16	14	69	15	14	72	21	12	-1.9	14.2	14	0.96	2.5	16.8	12	0.83
	PLA	98	30	15	105	53	14	92	25	11	4.9	28	14		-0.6	22.1	11	

689 **Table 3: Vital signs and selected safety labs.**


ALT	KE	20	10	14	18	8	14	17	6	12	-2.4	7.7	14	0.83	-0.9	3.5	12	0.74
	PLA	27	33	15	20	8	14	19	6	11	-7.5	30.7	14		0.5	3.9	11	
AST	KE	25	12	14	22	10	14	24	12	12	-3.4	6.1	14	0.83	-0.5	4.1	12	0.93
	PLA	23	14	15	20	5	14	20	4	11	-3.2	11.5	14		0.3	3.0	11	
Potassium	KE	4.7	0.5	14	4.6	0.4	14	4.6	0.3	12	-0.1	0.4	14	0.74	-0.1	0.5	12	0.96
	PLA	4.8	0.5	15	4.8	0.5	14	4.7	0.4	11	0.0	0.6	14		-0.1	0.5	11	

690 Vital signs, morphological data and selected safety labs (based on expected interaction with ketone biology) from older adults consuming KE or


PLA at baseline, week 4 visit and week 12 visit, and delta from baseline at both week 4 and week 12. P value is for KE vs PLA, * indicates p <

692 0.05. Abbreviations: BL, baseline; BP, blood pressure; KE, ketone ester; PLA, placebo; HR, heart rate; BPM, beats per minute.

693 Figure 1: Study Schematic



696 **Figure 2:**





Composite scores for all 10 items assessed in the Bevereage Tolerability Questionnaire (BTQ) either by daily
 duirng questionnaire during the two week acclimation period (A) or by bi-weekly phone interview in the post
 acclimation period (B). The maximum score is 30.

702

	KE	PLA
BO-BD (g)	25	0
Energy (kcal)	240	246
Carbohydrate (g)	2	2
Fat (g)	0.5	25
Protein (g)	2	2

703 Supplementary Table 1. Nutritional Information. Nutritional information for the KE and PLA beverages.

704 Abbreviations: BO-BD, bis-octanoyl (R)-1,3 butanediol; KE, ketone ester; PLA, placebo

706

		Acclimat	ion Period	Post Acclimation Period			
Symptom	Severity	Placebo	KE	Placebo	KE		
Any	Any	9 (60.0)	12 (85.7)	10 (71.4)	14 (100.0)		
	Mild	9 (60.0)	11 (78.6)	10 (71.4)	13 (92.9)		
	Moderate/Severe	4 (26.7)	6 (42.9)	5 (35.7)	7 (50.0)		
Abdominal cramping	Any	2 (13.3)	5 (35.7)	6 (42.9)	6 (42.9)		
	Mild	1 (6.7)	4 (28.6)	5 (35.7)	5 (35.7)		
	Moderate/Severe	1 (6.7)	3 (21.4)	2 (14.3)	1 (7.1)		
Burping	Any	4 (26.7)	5 (35.7)	3 (21.4)	4 (28.6)		
	Mild	4 (26.7)	5 (35.7)	3 (21.4)	4 (28.6)		
	Moderate/Severe	0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)		
Diarrhea	Any	4 (26.7)	4 (28.6)	5 (35.7)	4 (28.6)		
	Mild	4 (26.7)	3 (21.4)	5 (35.7)	3 (21.4)		
	Moderate/Severe	3 (20.0)	2 (14.3)	3 (21.4)	2 (14.3)		
Dizziness	Any	1 (6.7)	1 (7.1)	1 (7.1)	6 (42.9)		
	Mild	1 (6.7)	1 (7.1)	0 (0.0)	3 (21.4)		
	Moderate/Severe	1 (6.7)	1 (7.1)		3 (21.4)		
Jas	Any	4 (26.7)	5 (35.7)		4 (28.6)		
	Mild	4 (26.7)	5 (35.7)	1 (7.1) 5 (35.7) 5 (35.7) 2 (14.3)	4 (28.6)		
	Moderate/Severe	1 (6.7)	2 (14.3)		1 (7.1)		
Headache	Any	1 (6.7)	2 (14.3)	2 (14.3)	4 (28.6)		
	Mild	1 (6.7)	1 (7.1)	10 (71.4) 5 (35.7) 6 (42.9) 5 (35.7) 2 (14.3) 3 (21.4) 3 (21.4) 0 (0.0) 5 (35.7) 5 (35.7) 3 (21.4) 1 (7.1) 0 (0.0) 1 (7.1) 5 (35.7) 5 (35.7) 5 (35.7) 2 (14.3)	4 (28.6)		
	Moderate/Severe	1 (6.7)	1 (7.1)		1 (7.1)		
Nausea	Any	2 (13.3)	3 (21.4)		4 (28.6)		
	Mild	2 (13.3)	2 (14.3)	2 (14.3)	3 (21.4)		
	Moderate/Severe	0 (0.0)	1 (7.1)	0 (0.0)	2 (14.3)		
Reflux	Any	1 (6.7)	4 (28.6)	1 (7.1)	5 (35.7)		
	Mild	1 (6.7)	3 (21.4)	1 (7.1)	4 (28.6)		
	Moderate/Severe	0 (0.0)	2 (14.3)		3 (21.4)		
Stomach rumbling	Any	4 (26.7)	4 (28.6)	3 (21.4)	2 (14.3)		
č	Mild	3 (20.0)	4 (28.6)		2 (14.3)		
	Moderate/Severe	2 (13.3)	1 (7.1)		0 (0.0)		
Vomiting	Any	0 (0.0)	0 (0.0)		0 (0.0)		
-	Mild	0 (0.0)	0 (0.0)		0 (0.0)		
	Moderate/Severe	0 (0.0)	0 (0.0)		0 (0.0)		

Supplementary Table 2. Symptom reports during bi-weekly phone interview, listed by 707


type and severity. Number of participants that reported during a bi-weekly phone interview 708 that the listed symptoms occurred at least once during the pre- (week 1 and 2) and post-

709

(week 3 – 12) acclimation phases of the study. Abbreviations: KE, ketone ester. 710

712 Supplementary Figure 1

CONSORT 2010 Flow Diagram





Kinetics KE Beverage n = 30









